Early positive data for schistosomiasis vaccine

A US study has shown that an experimental vaccine called "SchistoShield" successfully elicited a strong immune response and generated long-lasting immune memory against schistosomiasis, a parasitic disease that is spread across approximately 80 countries and affects around 250 million people worldwide. Clinical trials demonstrated that the vaccine stimulates cellular immune responses as well as memory cells of both B and T lymphocytes, which enhances the likelihood of sustained protection against the parasites. The next step involves conducting larger-scale trials to verify its effectiveness and safety on a broader level.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل